WO2003038441A3 - Procedes de criblage a base de proteines de la famille des cited - Google Patents

Procedes de criblage a base de proteines de la famille des cited Download PDF

Info

Publication number
WO2003038441A3
WO2003038441A3 PCT/GB2002/004997 GB0204997W WO03038441A3 WO 2003038441 A3 WO2003038441 A3 WO 2003038441A3 GB 0204997 W GB0204997 W GB 0204997W WO 03038441 A3 WO03038441 A3 WO 03038441A3
Authority
WO
WIPO (PCT)
Prior art keywords
protein
cited
tfap2
methods based
screening methods
Prior art date
Application number
PCT/GB2002/004997
Other languages
English (en)
Other versions
WO2003038441A2 (fr
Inventor
Jose Braganca
Fatima Marques
Shoumo Bhattacharya
Simon Bamforth
Helen Catherine Hurst
Jyrki Johannes Eloranta
Original Assignee
Isis Innovation
Jose Braganca
Fatima Marques
Shoumo Bhattacharya
Simon Bamforth
Helen Catherine Hurst
Jyrki Johannes Eloranta
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Isis Innovation, Jose Braganca, Fatima Marques, Shoumo Bhattacharya, Simon Bamforth, Helen Catherine Hurst, Jyrki Johannes Eloranta filed Critical Isis Innovation
Publication of WO2003038441A2 publication Critical patent/WO2003038441A2/fr
Publication of WO2003038441A3 publication Critical patent/WO2003038441A3/fr

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57415—Specifically defined cancers of breast
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Hospice & Palliative Care (AREA)
  • Toxicology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

La présente invention concerne un procédé permettant d'identifier in vitro des composés bloquant l'interaction entre une protéine de la famille des CITED et une protéine TFAP2, ces composés présentant ainsi une activité potentielle pour le traitement du cancer. A cet effet, on commence par réaliser un mélange entre un premier composant à base de protéines dont une protéine CITED, un second composant à base de protéines dont une protéine TFAP2, et un candidat composé. On met à incuber le mélange dans des conditions qui, en l'absence du candidat composé, permettraient la liaison de la protéine CITED à la protéine TFAP2. Il ne reste plus qu'à détecter les éventuelles liaisons de la protéine CITED à la protéine TFAP2. En l'occurrence, les composés qui bloquent la liaison de la protéine CITED à la protéine TFAP2 sont identifiés comme présentant une activité pharmacologique potentielle dans le traitement du cancer du sein.
PCT/GB2002/004997 2001-11-02 2002-11-04 Procedes de criblage a base de proteines de la famille des cited WO2003038441A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0126386.2 2001-11-02
GB0126386A GB0126386D0 (en) 2001-11-02 2001-11-02 Screening methods based on cited family proteins

Publications (2)

Publication Number Publication Date
WO2003038441A2 WO2003038441A2 (fr) 2003-05-08
WO2003038441A3 true WO2003038441A3 (fr) 2004-03-11

Family

ID=9925062

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2002/004997 WO2003038441A2 (fr) 2001-11-02 2002-11-04 Procedes de criblage a base de proteines de la famille des cited

Country Status (2)

Country Link
GB (1) GB0126386D0 (fr)
WO (1) WO2003038441A2 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8207314B2 (en) * 2003-05-16 2012-06-26 Sanofi Pasteur Limited Tumor antigens for prevention and/or treatment of cancer
EP1793003A1 (fr) * 2005-11-30 2007-06-06 Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts CITED4 en tant que marqueur de pronostic pour les tumeurs oligodendrogliales
JP5091497B2 (ja) * 2006-03-17 2012-12-05 宏宣 柳衛 ＴＢＣＥ遺伝子またはＣＩＴＥＤ２遺伝子に特異的なｓｉＲＮＡおよびその用途
US10501513B2 (en) * 2012-04-02 2019-12-10 Modernatx, Inc. Modified polynucleotides for the production of oncology-related proteins and peptides

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001068846A2 (fr) * 2000-03-17 2001-09-20 Isis Innovation Limited Proteine transactivatrice transcriptionnelle
WO2003000730A1 (fr) * 2001-06-21 2003-01-03 The General Hospital Corporation Composes qui modulent les actions oestrogeniques

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001068846A2 (fr) * 2000-03-17 2001-09-20 Isis Innovation Limited Proteine transactivatrice transcriptionnelle
WO2003000730A1 (fr) * 2001-06-21 2003-01-03 The General Hospital Corporation Composes qui modulent les actions oestrogeniques

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BRAGANCA J ET AL: "Human CREB-binding protein/p300-interacting transactivator with ED-rich tail (CITED) 4, a new member of the CITED family, functions as a co-activator for transcription factor AP-2", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOGICAL CHEMISTS, BALTIMORE, MD, US, vol. 277, no. 10, 8 March 2002 (2002-03-08), pages 8559 - 8565, XP002956485, ISSN: 0021-9258 *
YAHATA TETSURO ET AL: "The MSG1 non-DNA-binding transactivator binds to the p300/CBP coactivators, enhancing their functional link to the Smad transcription factors", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 275, no. 12, 24 March 2000 (2000-03-24), pages 8825 - 8834, XP002260912, ISSN: 0021-9258 *

Also Published As

Publication number Publication date
WO2003038441A2 (fr) 2003-05-08
GB0126386D0 (en) 2002-01-02

Similar Documents

Publication Publication Date Title
WO2004009622A3 (fr) Complexes de proteiniques de reseaux cellulaires fondant le developpement du cancer et d'autres maladies
EP1226434B8 (fr) Methodes d'execution de dosages par chromatographie magnetique
WO2000023564A3 (fr) Automatisation de la conception des proteines pour l'elaboration des bibliotheques de proteines
WO2003022028A3 (fr) Methodes, reactifs, kits et appareil d'analyse de fonction proteique
AU2003262998A1 (en) Signal search procedure for a position determination system
AU2002246702A1 (en) Method of screening for gpr40 ligands
EP1102988B8 (fr) Procede d'evaluation de l'activite de la reponse immunitaire du sang et trousse d'essai correspondante
EP1090294A4 (fr) Methodes de determination de la presence d'un cancer dans un echantillon par determination de l'expression d'un gene ssx, peptides derives de ce gene ssx et du gene ny-eso-1 et leurs utilisations
AU1785099A (en) Novel gene having reverse transcriptase motif
WO2003038441A3 (fr) Procedes de criblage a base de proteines de la famille des cited
WO2003064622A3 (fr) Molecules d'aggrecanase
IL157047A0 (en) Methods and devices for quantitation of glycated protein
WO2005019475A3 (fr) Proteine 2 inductible par l'hypoxie (hig2), nouvelle cible therapeutique potentielle de l'hypernephrome (rcc)
WO2001085980A3 (fr) Tests enzymatiques destines au criblage d'agents anticancereux
WO2003020005A3 (fr) Proteines de mammiferes lp et reactifs associes
WO2003093817A3 (fr) Methode d'identification de ligands de recepteurs nucleaires
WO2004078783A3 (fr) Enzymes impliquees dans l'apoptose
AU4908799A (en) Determination of the hydrophobic pulmonary surfactant protein sp-c
WO2006039367A3 (fr) Systeme et procede de transfert d'energie par resonance
WO2002057792A3 (fr) Criblage de proteines hydrophobes par selection d'affinites
EP1183330A4 (fr) Kv10, un nouveau canal potassique commande par tension a partir de cerveau humain
WO2002033084A3 (fr) Identification de la glycoproteine du groupe sanguin dombrock utilisee en tant qu'element polymorphe de la famile du gene de l'adp/ribosyltransferase
MXPA05010062A (es) Metodo de deteccion selectiva de ligandos objetivo.
WO2002074906A3 (fr) Proteines de mammiferes lp et reactifs associes
AU2606800A (en) Methods of determining an increased risk of a woman carrying a downs syndrome

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP